Categories: Clinical TrialNews

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023.

Fireside Chat Details
Date: December 5, 2023
Time: 12:00 p.m. ET
Please register here to attend the live webinar.

An archived replay of the event will be available on the Company’s website here.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, please visit GainTherapeutics.com and follow us on LinkedIn.

Investor & Media Contact:

Susan Sharpe
Linnden Communications
(919) 602-2330
susan@linndencom.com

 

Staff

Recent Posts

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

3 hours ago

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

3 hours ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

3 hours ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

3 hours ago

Butterfly Network’s RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment

Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1,…

3 hours ago

Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized…

3 hours ago